Form 4: Incyte EVP Christiana Stamoulis Reports Stock and Option Awards

Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reports the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover tax obligations.

Summary

• On July 15, 2024, Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reported transactions involving Incyte's common stock.
• Stamoulis acquired 12,572 restricted stock units (RSUs) that vest 25% annually over four years.
• She also acquired 28,127 employee stock options exercisable in installments starting one year from the grant date, vesting monthly over three years thereafter, at an exercise price of $64.25.
• 948 shares were disposed of to satisfy tax withholding obligations at a price of $64.25 per share.
• Following these transactions, Stamoulis beneficially owns 95,197 shares of common stock, including 58,275 shares issuable pursuant to previously reported RSUs and earned performance shares that have not vested, and 28,127 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects standard executive compensation practices. The acquisition of RSUs and options is a positive sign, but the tax-related disposition is a neutral event.

Positives

• The acquisition of RSUs and stock options suggests confidence in Incyte's future performance.

Negatives

• The disposition of shares to cover tax obligations reduces Stamoulis' direct holdings, although this is a common practice.

Risks

• The value of the RSUs and stock options is dependent on Incyte's stock price, which is subject to market fluctuations and company performance.
• The vesting of the RSUs and options is contingent upon continued employment with Incyte.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and provide transparency into executive compensation and ownership. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common component of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of 25% annually over four years are typical for RSU grants.
• Tax withholding practices are standard when RSUs vest, resulting in the disposition of shares to cover the tax liability.

Stakeholder Impact

• Shareholders may view the RSU and option grants as an incentive for management to drive long-term value.
• Employees may be motivated by the potential for equity ownership.

Key Dates